NASDAQ$MRUS
Merus Nv · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Merus reported financial results for Q4 and full year 2019 and provided a business update.
Merus N.V. announced financial results for the fourth quarter and full year ended December 31, 2019. The company's cash, cash equivalents and marketable securities totaled $241.8 million at the end of 2019, and the company expects to be funded into 2022.
- Encouraging, early clinical activity in zenocutuzumab program for NRG1+ cancers.
- Phase 1/2 eNRGy trial enrollment continues for NRG1+ cancers.
- Phase 2 interim analysis reported for metastatic breast cancer trial.
- Cash runway extended, Merus expects to be funded into 2022 through first follow-on offering.
Headline financials
Revenue & EPS history
Merus · Revenue · Quarterly
$9.74M
Forward guidance
Based on the Company’s current operating plan, the Company expects its existing cash, cash equivalents and investments will be sufficient to fund its operations into 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
+0.5%
Avg return
Earnings day
-1.1%
Avg return
5 days after
-0.7%
Avg return
30 days after
49%
19 / 39 earnings
Positive
+19.7%
Q3 2023
Best reaction
-16.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -0.2% | +0.2% | +1.0% | |
| Q2 2025 | -2.8% | -4.2% | +0.1% | |
| Q1 2025 | -0.3% | +0.4% | +28.4% | |
| Q4 2024 | +1.5% | +3.6% | -18.8% | |
| Q3 2024 | -1.9% | +0.8% | -12.4% | |
| Q2 2024 | -1.8% | -5.8% | -4.3% | |
| Q1 2024 | -7.4% | -5.8% | +8.7% | |
| Q4 2023 | -0.9% | +2.3% | -8.1% | |
| Q3 2023 | +19.7% | — | — | |
| Q2 2023 | -11.7% | — | — | |
| Q1 2023 | +9.9% | — | — | |
| Q4 2022 | +4.0% | — | — | |
| Q3 2022 | -16.2% | — | — | |
| Q2 2022 | -8.4% | — | — | |
| Q1 2022 | +0.8% | — | — | |
| Q4 2021 | +6.4% | — | — | |
| Q3 2021 | +8.1% | — | — | |
| Q2 2021 | +3.0% | — | — | |
| Q1 2021 | -3.8% | — | — | |
| Q4 2020 | +3.2% | — | — | |
| Q3 2020 | -3.2% | — | — | |
| Q2 2020 | -1.5% | — | — | |
| Q1 2020 | +3.5% | — | — | |
| Q4 2019 | +11.9% | — | — | |
| Q3 2019 | -0.8% | — | — | |
| Q2 2019 | +7.7% | — | — | |
| Q1 2019 | +3.0% | — | — | |
| Q4 2018 | +3.8% | — | — | |
| Q3 2018 | +2.5% | — | — | |
| Q2 2018 | -2.8% | — | — | |
| Q1 2018 | -1.1% | — | — | |
| Q4 2017 | +2.6% | — | — | |
| Q3 2017 | -7.1% | — | — | |
| Q2 2017 | +5.0% | — | — | |
| Q1 2017 | +0.1% | — | — | |
| Q4 2016 | -3.5% | — | — | |
| Q3 2016 | +4.2% | — | — | |
| Q2 2016 | -1.5% | — | — | |
| Q1 2016 | -3.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro